Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT02286492. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of the program is to provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102 is clinically indicated.
Study identification
- NCT ID
- NCT02286492
- Recruitment status
- Approved For Marketing
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Sep 5, 2024
United States locations
- U.S. sites
- 33
- U.S. states
- 23
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama Oncology | Birmingham | Alabama | 35211 | — |
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| California Cancer Associates for Research and Excellence | Fresno | California | 93720 | — |
| Global Cancer Research Institute (GCRI), Inc. | Gilroy | California | 95020 | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Pacific Hematology Oncology Associates (PHOA) | San Francisco | California | 94115 | — |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Georgetown Lombardi Comprehensive Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| University of Florida Health Davis Cancer Center | Gainesville | Florida | 32610 | — |
| Ocala Oncology Center | Ocala | Florida | 34471 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| The University of Chicago | Chicago | Illinois | 60637 | — |
| Illinois CancerCare, P.C. | Peoria | Illinois | 61615-7828 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| University of Michigan Hospital | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| The Mark H. Zangmeister Center | Columbus | Ohio | 43219 | — |
| Hematology and Oncology Associates of Northeastern Pennsylvania | Dunmore | Pennsylvania | 18512 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Texas Oncology Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| Fox Valley Hematology & Oncology | Appleton | Wisconsin | 54915 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02286492, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 5, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02286492 live on ClinicalTrials.gov.